US OptionsDetailed Quotes
COGT250117C11000
- 0.50
- 0.000.00%
15min DelayTrading Dec 10 11:24 ET
0.00High0.00Low
0.00Open0.50Pre Close0 Volume80 Open Interest11.00Strike Price0.00Turnover228.47%IV41.63%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier11DDays to Expiry0.50Extrinsic Value100Contract SizeAmericanOptions Type0.2952Delta0.1060Gamma16.24Leverage Ratio-0.0518Theta0.0006Rho4.79Eff Leverage0.0049Vega
Cogent Biosciences Stock Discussion
based on a quick AI research:
AdvSM is very rare. Estimated 5,000-10,000 patients in US. Limited total market size.
Based on the recent clinical data, here are Cogent Biosciences' potential advantages:
1. Efficacy Advantages:
◦ 83% ORR (mIWG criteria)
◦ 100% ORR (PPR criteria)
– Higher response rate at optimal dose (100mg BID):
– Quick response time (2.2 months)
– Potentially better than existing treatments
1. Potential Market Differentiati...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
Positive
Strong 83% ORR in 100 mg BID dose cohort
94% of patients achieved ≥50% reduction in serum tryptase levels
Rapid median time to response of 2.2 months
82% progression-free survival rate at 24 months
100% of evaluable patients achieved ≥50% reduction in bone marrow mast cell burden
Negative
12 pat...
52% ORR per mIWG criteria, including 83% ORR for patients receiving 100 mg BID
88% ORR per PPR criteria, including 100% ORR for patients receiving 100 mg BID
Median time to response 2.2 months with median duration of response and median PFS not yet reach...
Cogent Biosciences Inc: Summit Trial Showed Clinically Meaningful Improvement in Skin Symptoms as Well as Objective Reduction in Skin Lesions
The company said the combination treatment led to a disease control rate of 80% in all patients and 100% in patients that were previously treated with imatinib only.
"Coupled with the impressive clinical activ...
Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
In a significant development for the biotech industry, Cogent Biosciences has announced positive Part 1b data from its SUMMIT trial evaluating Bezuclastinib, a novel targeted therapy, in patients with nonadvanced systemic mastocytosis (SM). The news marks a major milestone in the ongoing efforts to d...
GlobeNewswire· 30 mins ago
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...
No comment yet